Bioniche gets FDA fast-track status for bladder cancer product

By Elaine Rigoli

Tampa, Fla., May 4 - Bioniche Life Sciences, Inc. said the Food and Drug Administration has granted fast-track designation for the company's mycobacterial cell wall-DNA complex (Urocidin) for the treatment of non-muscle invasive bladder cancer in patients who are unresponsive to Bacillus Calmette-Guérin (BCG), the current standard therapy.

BCG is a live, attenuated strain of mycobacterium bovis, a therapy that is often associated with treatment-limiting side effects, according to a news release.

Bioniche, based in Belleville, Ont., is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of proprietary products for human and animal health markets worldwide.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.